$10.39
−4.33%Sep 9, 2026, 11:30 UTC
Kazia Therapeutics announced that the first patient has been dosed in Arm A of the PNOC035 Phase 2 clinical study evaluating paxalisib in combination with gemcitabine for recurrent or progressive AT/RT brain cancer in patients aged 1 to 39.
Source:Sep 1, 2026, 11:58 UTC
Kazia Therapeutics expanded its paxalisib clinical trial into HR+/HER2- breast cancer.
Source:Aug 27, 2026, 20:09 UTC
Kazia Therapeutics Limited announced a tranched registered public offering of American Depositary Shares, pre-funded warrants, and accompanying Series A and Series B warrants to purchase ADSs.
Aug 27, 2026, 20:01 UTC
Kazia Therapeutics announced new clinical data for its lead asset paxalisib in advanced triple-negative breast cancer, reporting a 100% clinical benefit rate in six evaluable patients.
Source: